JPMorgan Downgrades Pharmacyclics (PCYC) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. AAPL
2. BRZE
3. TTAN
4. CHYM
5. USO
6. COO
7. IRT
8. QCOM
9. AEO
10. MSI

Go back to JPMorgan Downgrades Pharmacyclics (PCYC) to Neutral

Pharmacyclics (PCYC) Remains Rated Sector Perform at RBC, PT Raised to $145

February 19, 2015 9:04 AM EST

RBC Capital maintained a Sector Perform rating on Pharmacyclics (NASDAQ: PCYC) and raised its price target to $145.00 (from $130.00). Comments follow Q4 results. Analyst Michael J. Yee thinks bulls are in control of the stock.

"We predict stock likely to keep trending up... More

Nomura Securities Upgrades Pharmacyclics (PCYC) to Buy

February 19, 2015 6:59 AM EST

Nomura Securities upgraded Pharmacyclics (NASDAQ: PCYC) from Neutral to Buy with a price target of $196.00 (from $195.00), saying the RESONATE-2 data is key to upside in 2015

Analyst M. Ian Somaiya commented, "Pharmacyclics management reaffirmed their 2015 US sales guidance of $1bn and more importantly confirmed results of... More

UPDATE: Roth Capital Cuts Pharmacyclics (PCYC) to Neutral; Sees FY15 Guidance, Market Expectations Priced into Shares

February 19, 2015 6:56 AM EST

(Updated - February 19, 2015 8:59 AM EST)

Roth Capital cuts Pharmacyclics (Nasdaq: PCYC) from Buy to Neutral and moves its price target from $189 to $187 following FY14 results reported on Wednesday night.

After markets close, Pharmacyclics posted Q4 EPS of $0.96 on revs of $290... More

Pharmacyclics (PCYC) Tops Q4 EPS by 20c

February 18, 2015 4:02 PM EST

Pharmacyclics (NASDAQ: PCYC) reported Q4 EPS of $0.96, $0.20 better than the analyst estimate of $0.76. Revenue for the quarter came in at $290 million versus the consensus estimate of $267.5 million.

Worldwide Collaboration and License Agreement with Janssen

Under the Agreement, the repayment of... More